{"id":"W2997722341","doi":"10.3747/co.26.5085","title":"Preferences of Canadian Patients and Physicians for Adjuvant Treatments for Melanoma","year":2019,"lang":"en","type":"article","venue":"Current Oncology","topic":"Cutaneous Melanoma Detection and Management","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"ca_institutions":"Novartis (Canada)","funders":"","keywords":"Medicine; Trametinib; Dabrafenib; Pembrolizumab; Melanoma; Adverse effect; Family medicine; Regimen; Internal medicine; Adjuvant; Quality of life (healthcare); Cancer; Oncology; Vemurafenib; Metastatic melanoma; Immunotherapy; Nursing","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":true,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002061771,0.0002125434,0.0002308446,0.000346678,0.001544102,0.0009074468,0.0002289535,0.0006612095,0.00630835],"category_scores_gemma":[0.009759477,0.0001273997,0.0004779488,0.0005615079,0.000680636,0.0002857701,0.000342441,0.0006185109,0.0003709568],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00607202,"about_ca_system_score_gemma":0.006551981,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.5163622,"about_ca_topic_score_gemma":0.6543504,"domain_scores_codex":[0.9978497,0.000725121,0.00008596702,0.0001510012,0.0007471705,0.0004410708],"domain_scores_gemma":[0.9944515,0.001955909,0.001231251,0.0001741471,0.0009132933,0.001273892],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.003008177,0.0006304147,0.9160872,0.0001677483,0.0001627806,0.0003457969,0.007657965,0.0008895183,0.001570316,0.0007331782,0.01274426,0.05600262],"study_design_scores_gemma":[0.000523749,0.001023059,0.9636557,0.0001430613,0.0001399335,0.0008587763,0.01141215,0.001902387,0.0006119478,0.0004818158,0.01912268,0.0001247403],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9902834,0.0004748889,0.0001004827,0.001451361,0.00001782881,0.00006769678,0.0005895174,0.000004417606,0.00701037],"genre_scores_gemma":[0.9973028,0.0002423317,0.0003010608,0.0009640921,0.00001356539,0.00002356874,0.0002463597,0.000001440384,0.000904735],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4836378,"threshold_uncertainty_score":0.9729721,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06610240493853994,"score_gpt":0.3426464521618954,"score_spread":0.2765440472233555,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}